Title: A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis (LUCENT-ACT)
Associated condition: Ulcerative colitis
Status: Currently enrolling
Brief summary: The purpose of this study is to evaluate if study drug mirikizumab is safe and effective compared to vedolizumab and placebo in participants with moderately to severely active ulcerative colitis (UC).
Primary objectives: Percentage of Participants in Histologic Remission [Time Frame: Week 12]
Histologic remission based on histology.
Estimated length of study: Estimated that the study be fully completed in June 2024.
For more detailed information on this research trial, including eligibility and study design, please visit the clinical trial page at U.S. National Library of Medicine’s website. Note you can submit your information for consideration by submitting the contact form on this page.